Abiopharma

Investis Notification - Smith+Nephew PLC

Johnson & Johnson - Johnson & Johnson investigational co-antibody therapy JNJ-4804 shows potential to raise the bar for clinical efficacy in treating refractory inflammatory bowel disease

Johnson & Johnson - Johnson & Johnson study showsTREMFYA® (guselkumab) is the first and only IL-23 inhibitor to demonstrate efficacy in perianal fistulizing Crohns disease

Johnson & Johnson investigational co-antibody therapy JNJ-4804 shows potential to raise the bar for clinical efficacy in treating refractory inflammatory bowel disease

Johnson & Johnson study shows TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to demonstrate efficacy in perianal fistulizing Crohn's disease

AbbVie Highlights New Long-Term Data Advancing Treatment Standards in Inflammatory Bowel Diseases (IBD) at 2026 Digestive Disease Week®

Elkhart Clinic Joins American Oncology Network, Becomes Elkhart Hematology and Oncology

Corbus Pharmaceuticals to Host In-Person and Virtual KOL Event at ASCO 2026

Net Asset Value(s)

Mineros S.A. Achieves Major Milestone With Porvenir Project Development